AnaptysBio (NASDAQ:ANAB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of AnaptysBio (NASDAQ:ANAB) from a buy rating to a strong-buy rating in a research report released on Sunday morning.

Several other equities research analysts have also weighed in on the company. HC Wainwright dropped their target price on AnaptysBio from $59.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. Stifel Nicolaus raised their target price on shares of AnaptysBio from $55.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Guggenheim boosted their target price on AnaptysBio from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. boosted their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus price target of $59.40.

AnaptysBio Price Performance

Shares of AnaptysBio stock opened at $37.01 on Friday. The company has a market capitalization of $1.02 billion, a PE ratio of -13.12 and a beta of 0.16. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $40.96. The business has a 50-day moving average of $30.59 and a 200-day moving average of $25.37.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The business had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. On average, equities analysts expect that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ANAB. US Bancorp DE raised its stake in shares of AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 979 shares in the last quarter. Larson Financial Group LLC boosted its holdings in AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the last quarter. Finally, Osaic Holdings Inc. increased its position in shares of AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.